• Je něco špatně v tomto záznamu ?

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir

D. Abt, A. Besse, L. Sedlarikova, M. Kraus, J. Bader, T. Silzle, M. Vodinska, O. Slaby, HP. Schmid, DS. Engeler, C. Driessen, L. Besse,

. 2018 ; 121 (4) : 600-609. [pub] 20171210

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001082

OBJECTIVES: To assess the potential of second-generation proteasome inhibition by carfilzomib and its combination with the human immunodeficiency virus (HIV) protease inhibitors (HIV-PIs) lopinavir and nelfinavir in vitro for improved treatment of clear cell renal cell cancer (ccRCC). MATERIALS AND METHODS: Cytotoxicity, reactive oxygen species (ROS) production, and unfolded protein response (UPR) activation of proteasome inhibitors, HIV-PIs, and their combination were assessed in three cell lines and primary cells derived from three ccRCC tumours by MTS assay, flow cytometry, quantitative reverse transcriptase-polymerase chain reaction and western blot, respectively. Proteasome activity was determined by activity based probes. Flow cytometry was used to assess apoptosis by annexin V/propidium iodide assay and ATP-binding cassette sub-family B member 1 (ABCB1) activity by MitoTrackerTM Green FM efflux assay (Thermo Fisher Scientific, MA, USA). RESULTS: Lopinavir and nelfinavir significantly increased the cytotoxic effect of carfilzomib in all cell lines and primary cells. ABCB1 efflux pump inhibition, induction of ROS production, and UPR pre-activation by lopinavir were identified as underlying mechanisms of this strong synergistic effect. Combined treatment led to unresolved protein stress, increased activation of pro-apoptotic UPR pathway, and a significant increase in apoptosis. CONCLUSION: The combination of the proteasome inhibitor carfilzomib and the HIV-PIs lopinavir and nelfinavir has a strong synergistic cytotoxic activity against ccRCCin vitro at therapeutically relevant drug concentrations. This effect is most likely explained by synergistic UPR triggering and ABCB1-modulation caused by HIV-PIs. Our findings suggest that combined treatment of second-generation proteasome inhibitors and HIV-PIs should be investigated in patients with metastatic RCC within a clinical trial.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001082
003      
CZ-PrNML
005      
20240312105527.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bju.14083 $2 doi
035    __
$a (PubMed)29161753
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Abt, Dominik $u Department of Urology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
245    10
$a Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir / $c D. Abt, A. Besse, L. Sedlarikova, M. Kraus, J. Bader, T. Silzle, M. Vodinska, O. Slaby, HP. Schmid, DS. Engeler, C. Driessen, L. Besse,
520    9_
$a OBJECTIVES: To assess the potential of second-generation proteasome inhibition by carfilzomib and its combination with the human immunodeficiency virus (HIV) protease inhibitors (HIV-PIs) lopinavir and nelfinavir in vitro for improved treatment of clear cell renal cell cancer (ccRCC). MATERIALS AND METHODS: Cytotoxicity, reactive oxygen species (ROS) production, and unfolded protein response (UPR) activation of proteasome inhibitors, HIV-PIs, and their combination were assessed in three cell lines and primary cells derived from three ccRCC tumours by MTS assay, flow cytometry, quantitative reverse transcriptase-polymerase chain reaction and western blot, respectively. Proteasome activity was determined by activity based probes. Flow cytometry was used to assess apoptosis by annexin V/propidium iodide assay and ATP-binding cassette sub-family B member 1 (ABCB1) activity by MitoTrackerTM Green FM efflux assay (Thermo Fisher Scientific, MA, USA). RESULTS: Lopinavir and nelfinavir significantly increased the cytotoxic effect of carfilzomib in all cell lines and primary cells. ABCB1 efflux pump inhibition, induction of ROS production, and UPR pre-activation by lopinavir were identified as underlying mechanisms of this strong synergistic effect. Combined treatment led to unresolved protein stress, increased activation of pro-apoptotic UPR pathway, and a significant increase in apoptosis. CONCLUSION: The combination of the proteasome inhibitor carfilzomib and the HIV-PIs lopinavir and nelfinavir has a strong synergistic cytotoxic activity against ccRCCin vitro at therapeutically relevant drug concentrations. This effect is most likely explained by synergistic UPR triggering and ABCB1-modulation caused by HIV-PIs. Our findings suggest that combined treatment of second-generation proteasome inhibitors and HIV-PIs should be investigated in patients with metastatic RCC within a clinical trial.
650    _2
$a antitumorózní látky $x terapeutické užití $7 D000970
650    _2
$a karcinom z renálních buněk $x farmakoterapie $7 D002292
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chemorezistence $7 D019008
650    _2
$a stres endoplazmatického retikula $x účinky léků $7 D059865
650    _2
$a inhibitory HIV-proteasy $x terapeutické užití $7 D017320
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x farmakoterapie $7 D007680
650    _2
$a Lopinavir $x terapeutické užití $7 D061466
650    _2
$a nelfinavir $x terapeutické užití $7 D019888
650    _2
$a inhibitory proteasomu $x terapeutické užití $7 D061988
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Besse, Andrej $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Sedlarikova, Lenka $u Department of Pathological Physiology, Babak Myeloma Group, Masaryk University, Brno, Czech Republic.
700    1_
$a Kraus, Marianne $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Bader, Juergen $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Silzle, Tobias $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Vodinská, Martina $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. $7 xx0314713
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Schmid, Hans-Peter $u Department of Urology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Engeler, Daniel Stephan $u Department of Urology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Driessen, Christoph $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
700    1_
$a Besse, Lenka $u Experimental Oncology and Hematology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
773    0_
$w MED00011371 $t BJU international $x 1464-410X $g Roč. 121, č. 4 (2018), s. 600-609
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29161753 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20240312105524 $b ABA008
999    __
$a ok $b bmc $g 1365015 $s 1039205
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 121 $c 4 $d 600-609 $e 20171210 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
LZP    __
$a Pubmed-20190107
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace